Listed

Milestone Scientific Inc.: Form 10-Q for the period ended Mar 31, 2018

Filed with the SEC on May 15, 2018 and accepted by EDGAR at May 15, 2018, 16:03 ET.

Share

Management's discussion and analysis

As filed, 19,038 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussions of the financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements included elsewhere in this annual report. Certain statements in this discussion and elsewhere in this report constitute forward-looking statements, within the meaning of section 21E of the Exchange Act, that involve risks and uncertainties. The actual results may differ materially from those anticipated in these forward-looking statements.

OVERVIEW

Milestone Scientific is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and devices for medical, dental, cosmetic and veterinary applications. Since our inception, we have engaged in pioneering proprietary, innovative, computer-controlled injection technologies and solutions for the medical and dental markets. We have focused our resources on redefining the worldwide standard of care for injection techniques by making the experience more comfortable for the patient by reducing the anxiety and stress of receiving injections from the healthcare provider. Our computer-controlled injection systems make injections precise, efficient and virtually painless. Milestone’s proprietary DPS Dynamic Pressure Sensing technology is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections.

Milestone Scientific remains focused on advancing efforts to achieve the following five primary objectives:

  • Establishing Milestone’s DPS Dynamic Pressure Sensing technology platform as the standard-of-care in painless and precise drug delivery, providing for the first time objective

visual and audible in-tissue pressure feedback, and continuing to expand platform applications;

  • Following obtaining successful FDA clearance of our first medical device in June 2017, Milestone Scientific is transitioning from a research and development organization to

a commercially focused medical device company;

  • Commercializing our CompuFlo Epidural System, a transformative device for epidural anesthesia procedures;
  • Expanding the global footprint of our CompuFlo Epidural System by partnering with distribution companies worldwide; and
  • Continuing the commercial launch and gain regulatory approval of our proprietary cosmetic injection device for delivery of botulinum toxin (such as Botox® and Dysport®).

Distribution and Marketing Arrangements

Our dental devices are sold in the United States, Canada, and in over 53 countries abroad. In June 2017, we received FDA regulatory clearance to sell our first medical device, the CompuFlo Epidural System in the United States. Since receiving FDA clearance in 2017 our epidural devices have had minimal sales in the United States and Europe.

Dental Market

In the spring of 2009, Milestone Scientific signed a distribution and marketing agreement with China National Medicines Corporation, dba Sinopharm. In early October 2012, the State Food and Drug Administration (“CFDA”) of the People’s Republic of China approved the Wand STA System. However, the CFDA’s approval of the Wand STA handpieces was not received until May 2014 and the distribution of these handpieces in China began in the fourth quarter of 2014. The distribution and marketing agreement with Sinopharm was terminated in September 2014. Proximate to that time, we entered into a new agreement with Milestone China to be our distributor for the Wand STA System and handpieces in China.

In November 2012, Milestone Scientific signed an exclusive distributor and marketing agreement with a well-known U.S. domestic manufacturer and distributor, for the sale and distribution of the Wand STA System and handpieces in the United States and Canada. The marketing initiative included participation in United States and Canadian dental shows, as well as pediatric dental shows; an active advertising initiative targeting major dental publications; and direct mailing campaigns to over 150,000 dentists across the United States and Canada. This exclusive distributor and marketing agreement was converted to a non-exclusive agreement as of December 31, 2016.

Beginning January 1, 2016, Milestone Scientific entered into a non-exclusive distribution agreement with Henry Schein. In June 2016, that agreement was replaced by a new agreement with Henry Schein providing for an exclusive distribution arrangement for our dental products in the United States and Canada by a newly formed marketing and sales group at Henry Schein. Under this arrangement, we have a semi-dedicated independent sales force visiting dentists. Henry Schein’s exclusive products sales specialist team, which is comprised of 25 sales representatives and supported by over 1,000 field service representatives, will exclusively market and distribute the Wand STA System and handpieces, together with a select group of other devices in the United States and Canada.

Our agreement with Henry Schein has minimum purchase orders to maintain exclusivity in the third through tenth years. We believe that this exclusive arrangement will be more effective than previous arrangements relying on Wand Dental's appearances at dental shows and catalog sales.

Medical Market

Having received FDA clearance to sell the CompuFlo Epidural System in June 2017, we are in discussions with a small number of regional and national distributors. Our immediate focus is on marketing our epidural device throughout Europe.

In February and March 2018, Milestone Scientific hired an Executive VP of Global Sales and Marketing and a Vice President of US Sales to fill a significant gap in our commercialization efforts of the CompuFlo Epidural System.

We have entered into a limited number of distributor arrangements in Europe and the Middle East for our CompuFlo Epidural Computer Controlled Anesthesia System. Our distribution strategy is initially aimed at having KOLs use and accept the device and initiate their own studies.

The following table shows a breakdown of Milestone Scientific’s product sales (net), domestically and internationally, by business segment product category:

Domestic US / Canada: Three months ended March 31, 2018 Reportable Segments Dental Medical Total 2017 Reportable Segments Dental Medical Total
Device $ 121,048 $ - $ 121,048 $ 185,645 $ - $ 185,645
Handpieces 768,531 - 768,531 1,510,486 - 1,510,486
Other 28,851 - 28,851 18,941 - 18,941
Total Domestic US / Canada 918,430 - 918,430 1,715,072 - 1,715,072
International Rest of the World:
Device 246,968 32,500 279,468 358,670 - 358,670
Handpieces 578,827 4,000 582,827 583,349 - 583,349
Other 24,880 - 24,880 30,097 - 30,097
Total International Rest of the World 850,675 36,500 887,175 972,116 - 972,116
International China:
Device - - - 1,000,000 - 1,000,000
Handpieces - - - 1,800 - 1,800
Other - - - - - -
Total International China - - - 1,001,800 - 1,001,800
Total Product Sales $ 1,769,105 $ 36,500 $ 1,805,605 $ 3,688,988 $ - $ 3,688,988

22

Milestone Scientific plans to support increased sales and marketing activity through our current distributors and through newly appointed distributors of the Wand STA devices and handpieces in the international market. In the United States and Canada, Milestone Scientific will continue the utilization of independent hygienists for training individual practitioners and group practices domestically, refined and directed advertising to dental professionals, continue to develop Key Opinion Leaders (KOL) and support and broaden our global distribution network. Additionally, with the recent FDA marketing clearance for the CompuFlo Epidural System, Milestone Scientific is initiating marketing and sales efforts in the US to establish medical sector distributors for the sale of this device.

Current Product Platform

See Item 1. Description of Business.

Results of Operations

The following table sets forth for the consolidated results of operations for the three months ended March 31, 2018 compared to 2017 as a percentage of revenues. The trends suggested by this table may not be indicative of future operating results:

Operating results: Three Months Ended March 31, 2018 March 31, 2017
Net Sales $1,805,605 100% $3,688,988 100%
Cost of Sales 562,676 31% 1,402,285 38%
Gross Profit 1,242,929 69% 2,286,703 62%
Operating expenses:
Selling, general, and administrative 3,018,783 167% 2,707,620 73%
Research & development 225,817 13% 105,015 3%
Operating Loss $(2,001,668) -111% $(525,932) -14%
Other Expenses, net 26,283 1% (52,053) -1%
Net Loss (1,975,385) -109% (577,985) -16%
Net loss profit attributable to noncontrolling interest (101,407) -6% (73,117) 2%
Net loss attributable to Milestone Scientific Inc. $(1,873,978) -104% $(504,868) -14%
Cash flow: Three Months Ended March 31, 2018 March 31, 2017
Net cash used in operating activities $(541,350) $(874,010)
Net cash used in investing activities $(1,368) $-
Net cash provided by financing activities $- $213,336

Three Months ended March 31, 2018 compared to Three Months ended March 31, 2017

Net sales for three months ended March 31, 2018 and 2017 were as follows:

2018 2017 Increase (Decrease) $%
Dental $1,769,105 $3,688,988 $(1,919,883) -52.04%
Medical 36,500 - 36,500 100.00%
Total $1,805,605 $3,688,988 $(1,883,383) -51.05%

Consolidated revenue for the three months ended March 31, 2018 and 2017 were approximately $1.8 million and $3.7 million, respectively. Dental revenue for the three months ended March 31, 2018 and 2017 were approximately $1.8 million and $3.7 million, respectively. Dental revenue decreased by approximately $1.9 million, which is principally related to a decrease in sales to Milestone China (approximately $1.0 million) and a decrease of approximately $900,000 in USA and Canada domestic sales. The reduction in shipments to Milestone China is due to Milestone China working through inventory purchases form 2017 and modifications to their business strategy to better serve the China dental market. The USA and Canadian revenue is lower in the first quarter of 2018, as Henry Schein purchased additional inventories in the fourth quarter of 2017, to avoid a price increase effective in the first quarter of 2018. Medical revenue for the three months ended March 31, 2018 and 2017 were $36,500 and $0, respectively.

On June 12, 2017 the Company announced that the CompuFlo Epidural System received 510(k) marketing clearances from the U.S. Food and Drug Administration (FDA). Milestone is in the process of attending medical device trade shows and attending introductory meetings with medical device distributors within the United States and European markets. The Company’s focus is on marketing its CompuFlo Epidural System throughout Europe.

Gross Profit for three months ended March 31, 2018 and 2017 were as follows:

2018 2017 Increase (Decrease) $%
Dental $1,218,026 $2,286,703 $(1,068,677) -46.73%
Medical 24,903 - 24,903 100.00%
Total $1,242,929 $2,286,703 $(1,043,774) -45.65%

Consolidated gross profit for the three months ended March 31, 2018 and 2017 were approximately 69% and 62%, respectively. The improvement in gross profit percentage for the three months ended March 31, 2018 is due to the decrease in sales to Milestone China which sales have a reduced gross profit margin as Milestone China is expanding its market penetration. The gross profit dollars decreased by approximately $1.0 million due to lower revenues in the first quarter 2018.

Selling, general and administrative expenses for three months ended March 31, 2018 and 2017 were as follows:

2018 2017 Increase (Decrease) $%
Dental $860,861 $1,008,071 $(147,210) -14.60%
Medical 678,052 589,483 88,569 15.02%
Corporate 1,479,867 1,110,066 369,801 33.31%
Total $3,018,780 $2,707,620 $311,160 11.49%

Consolidated selling, general and administrative expenses for the three months ended March 31, 2018 and 2017 were approximately $3 million versus $2.7 million, respectively. The increase of approximately $311,000 is predominantly due to the increase in Corporate expenses. Milestone Scientific Corporate SG&A expenses increased by approximately $370,000 essentially all the increase represents (approx. $220,000) amortization of the patents acquired in the APAD purchase in 2017.

Research and Development for three months ended March 31, 2018 and 2017 were as follows:

2018 2017 Increase (Decrease) $%
Dental $- $3,000 $(3,000) -100.00%
Medical 55,233 34,844 20,389 58.52%
Corporate 170,584 67,171 103,413 153.95%
Total Sales $225,817 $105,015 $120,802 115.03%

Consolidated research and development expenses for the three months ended March 31, 2018 and 2017 were approximately $226,000 and $105,000, respectively. The increase is due to the development of the cosmetic injection device.

Profit (Loss) from Operations for three months ended March 31, 2018 and 2017 were as follows:

2018 2017 Increase (Decrease) $%
Dental $357,165 $1,275,631 $(918,466) -71.94%
Medical (708,382) (624,326) (84,056) 13.46%
Corporate (1,650,451) (1,177,237) (473,214) 40.26%
Total $(2,001,668) $(525,932) $(1,475,736) 280.60%

The loss from operations for the three months ended March 31, 2018 and 2017 was approximately $2 million and $526,000, respectively, an increase of approximately $1.5 million. This increase is primarily attribute to the reduction in net sales of $1.8 million, and an increase in selling, general and administrative of $311,000 as explained above, represents the increase loss of operations for the first quarter 2018.

Liquidity and Capital Resources

At March 31, 2018, Milestone Scientific had cash and cash equivalents of approximately $2.1 million, total current assets of approximately $11.0 million and working capital of approximately $4 million. We believe that our cash on hand, accounts receivable and the anticipated revenues from the dental business will be sufficient to fund our business operations for at least the next 12 months from the filing date of this Form 10-Q.

Milestone Scientific continues to take positive steps to maintain adequate inventory levels and advances on contracts to maintain available inventory to meet our domestic and international sales requirements. For the three months ended March 31, 2018 and 2017, we had cash flows used in operating activities of approximately $541,000 and $874,000, respectively.

Milestone Scientific has incurred annual operating losses and negative cash flows from operating activities since its inception. The capital raised in December 2016 and January 2017 provided Milestone Scientific with working capital to continue to develop its medical devices and obtain FDA regulatory clearance of its CompuFlo Epidural System, as well as to aggressively market its dental devices. Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, and a reduction in operating expenses.

Now that the CompuFlo Epidural System has obtained FDA clearance in the United States (June 2017), the Company’s development costs should be lower in 2018. The FDA clearance will provide the Company with the opportunity to establish distribution in the USA. At the same time, the Company is looking to establish additional financing opportunities to help with the commercialization of the Epidural device. The intra-articular device will begin the 510K application process in the second quarter of this year. Most of the cost associated with this application will be internal personnel cost and some low level third party review expense.

Milestone Scientific believes that the FDA clearance of its 510(k) application with respect to the CompuFlo Epidural System will provide Milestone Scientific with the opportunity to enter the US medical device market and generate revenues in the future. Milestone Scientific believes that it has sufficient inventory of epidural devices to satisfy the near-term marketing opportunities.

In February and March 2018 Milestone Scientific hired an Executive VP of Global sales and Marketing and a Vice President of US Sales to fill a significant gap in our commercialization efforts of the CompuFlo Epidural System.

Milestone Scientific believes that the June 2016 exclusive distribution agreement with Henry Schein will continue to improve its domestic revenues in 2018. The dental agreement has provided a substantial increase in US and Canada dental revenue in 2017 (approximately $2 million). To further reduce Milestone Scientific's expenditures, Milestone Medical is carefully managing expenses related to obtaining FDA clearance for the intra-articular devices.

Our condensed consolidated balance sheets included in this Quarterly Report reflects a decrease of approximately $1.0 million in current assets from December 31, 2017 to March 31, 2018. This decrease in current assets was primarily due to a reduction in cash, accounts receivable, and inventory of approximately $1,358,000. This was offset by increases in prepaid expenses and advances on contracts of an aggregate of approximately $345,000.

In this Quarterly Report our consolidated balance sheets included an increase in current liabilities of approximately $364,000 from approximately $7.0 million to approximately $6.7 million. The increase is primarily due to an increase in accounts payable of approximately $579,000, accounts payable related party of approximately $89,400, deferred profit related party of approximately 55,000 and a decrease in accrued expenses of approximately $359,000.

Market risk

As filed, 162 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Milestone Scientific is a “smaller reporting company” as defined by Regulation S-K and, as such, is not required to provide the information required by this item.

Controls and procedures

As filed, 1,377 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Milestone Scientific’s Interim Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of the design and operation of Milestone Scientific’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based upon that evaluation, Milestone Scientific’s Interim Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures as of March 31, 2018 are effective to ensure that information required to be disclosed in the reports Milestone Scientific files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to Milestone Scientific's management, including the Interim Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. There have been no changes in Milestone Scientific’s internal control over financial reporting identified in connection with the evaluation that occurred during Milestone Scientific’s last fiscal quarter ended March 31, 2018 that have materially affected, or that are reasonably likely to materially affect, Milestone Scientific’s internal controls over financial reporting.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2018-01-01 to 2018-03-31$1.8mus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
Cost of revenue3 months2018-01-01 to 2018-03-31$562.7kus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2018-01-01 to 2018-03-31$1.2mus-gaap:GrossProfit
Research and development3 months2018-01-01 to 2018-03-31$225.8kus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2018-01-01 to 2018-03-31$3.0mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2018-01-01 to 2018-03-31−$2.0mus-gaap:OperatingIncomeLoss
Income tax3 months2018-01-01 to 2018-03-31$11.5kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2018-01-01 to 2018-03-31−$1.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-01-01 to 2018-03-31−$0.06us-gaap:EarningsPerShareDiluted
Basic EPS3 months2018-01-01 to 2018-03-31−$0.06us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2018-01-01 to 2018-03-3134,766,014 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2018-01-01 to 2018-03-31−$541.4kus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2018-01-01 to 2018-03-31$1.4kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2018-03-31$2.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-03-31$11.0mus-gaap:AssetsCurrent
Total assetsAt period end2018-03-31$14.4mus-gaap:Assets
Current liabilitiesAt period end2018-03-31$7.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-03-31$8.4mus-gaap:Liabilities
Shareholders' equityAt period end2018-03-31$5.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001437749-18-009987. Last ingested by Listed: Nov 14, 2026, 11:14 ET. Listed shows no prices and gives no investment advice.